KP-100IT

DRUG3 trials

Sponsors

Kringle Pharma, Inc.

Conditions

Acute Spinal Cord InjuryAcute Spinal Cord Injury (SCI)Spinal Cord Injuries

Phase 1

Phase I/II Study of KP-100IT in Acute Spinal Cord Injury

CompletedNCT02193334

Kringle Pharma, Inc.Spinal Cord Injuries

Start: 2014-06-30End: 2018-07-31Updated: 2019-06-05

Phase 3

Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

Kringle Pharma, Inc.Acute Spinal Cord Injury

Start: 2020-07-13End: 2023-06-30Target: 25Updated: 2022-08-26

Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

Not yet recruitingNCT07722962

Kringle Pharma, Inc.Acute Spinal Cord Injury (SCI)

Start: 2026-07-31End: 2028-12-31Target: 10Updated: 2026-07-23

Related Papers

Translational Advances in the Management of Acute Spinal Cord Injury

Neurosurgery2017-04-0533 citations